Description: Novo Nordisk A/S engages in the discovery, development, manufacture, and marketing of pharmaceutical products primarily in Denmark. It operates in two segments, Diabetes Care and Biopharmaceuticals. The Diabetes Care segment covers insulins, GLP-1 analog, obesity, and oral antidiabetic drugs, as well as other protein related products comprising glucagon, protein related delivery systems, and needles. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth hormone therapy, hormone replacement therapy, and inflammation. The company sells its products primarily in North America, China, Japan, Algeria, Argentina, Australia, Brazil, India, Turkey, and European countries through its subsidiaries, distributors, and independent agents. Novo Nordisk A/S was founded in 1925 and is headquartered in Bagsvaerd, Denmark.
Home Page: www.novonordisk.com
NVO Technical Analysis
Novo Allé 1
Bagsvaerd,
2880
Denmark
Phone:
45 44 44 88 88
Officers
| Name | Title |
|---|---|
| Mr. Lars Fruergaard Jorgensen | Pres, CEO & Member of Management Board |
| Mr. Karsten Munk Knudsen | Exec. VP, CFO & Member of the Management Board |
| Mr. Henrik Ehlers Wulff | Exec. VP, Head of Product Supply, Quality & IT and Member of the Management Board |
| Ms. Camilla Sylvest | Exec. VP, Head of Commercial Strategy & Corp. Affairs and Member of the Management Board |
| Dr. Martin Holst Lange | Exec. VP, Head of Devel. & Member of the Management Board |
| Ms. Monique Carter | Exec. VP, Head of People & Organisation and Member of Management Board |
| Dr. Marcus Schindler Ph.D. | EVP, Head of Research & Early Devel., Chief Scientific Officer & Member of the Management Board |
| Mr. Maziar Mike Doustdar | Exec. VP, Head of International Operations & Member of the Management Board |
| Mr. Douglas J. Langa | Exec. VP, Head of North America Operations & Member of Management Board |
| Mr. Ludovic Helfgott | Exec. VP, Head of Rare Disease & Member of Management Board |
Exchange: NYSE
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 31.1526 |
|---|---|
| Trailing PE: | 39.9305 |
| Price-to-Book MRQ: | 27.8982 |
| Price-to-Sales TTM: | 1.7848 |
| IPO Date: | 1982-01-04 |
| Fiscal Year End: | December |
| Full Time Employees: | 52696 |